NCT05613413View on ClinicalTrials.gov

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 28, 2022

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
Metastatic Squamous Non-Small Cell Lung Carcinoma
Interventions
DRUG

Cabozantinib 40 MG

Cabozantinib is taken my mouth

DRUG

Pembrolizumab 200mg

Pembrolizumab is given intravenously

DRUG

Pembrolizumab 400mg

Pembrolizumab is given intravenously

Trial Locations (1)

60612

RECRUITING

Ryan Nguyen, Chicago

All Listed Sponsors
lead

University of Illinois at Chicago

OTHER